Researchers at Virginia Tech are building a new organ-on-a-chip system designed to make drug testing more realistic, starting with one of the body’s toughest barriers: the blood-brain barrier. That barrier is the protective lining of cells that controls what can move from the bloodstream into the brain, and it is a major reason many promising drugs fail. The team’s approach combines high-resolution 3D printing, ultra-thin membranes, and living cells to create a lab model that behaves more like human tissue than standard flat cell cultures. At the center of the project is a proprietary 3D-printing method from the Virginia Tech spinout Phase, which the researchers say can produce microfluidic structures at unusually small scales while remaining reproducible and scalable. Microfluidics are tiny devices with channels that guide minute amounts of fluid, a bit like plumbing shrunk down to the size of a laboratory slide. By using those channels to expose cells to flowing liquids and carefully controlled conditions, scientists can recreate some of the physical cues that cells experience inside the body. Although the first target is the blood-brain barrier, the same platform could be adapted for organs such as the liver, lungs, and skin. The long-term goal is not just better lab models, but drug tests that are faster, more informative, and potentially customizable to individual patients.
Why the blood-brain barrier is such a hard problem
The blood-brain barrier, often shortened to BBB, acts like a highly selective security checkpoint for the brain. It lets needed molecules pass through while blocking many toxins, pathogens, and drugs, which is essential for health but frustrating for drug developers.
That creates a practical problem: a treatment can look promising in a dish and still fail because it cannot actually reach brain tissue in the body. A more faithful BBB model could help researchers see those limits earlier and design better compounds before moving into expensive animal studies or clinical trials.
How the chip is built
The Virginia Tech effort relies on a 3D-printing technique developed through Phase that can fabricate microfluidic devices at resolutions the team describes as previously unattainable, while also keeping production consistent from one device to the next. In research tools, that consistency matters because small manufacturing differences can change how cells grow and how fluids move.
An easy way to picture the device is to imagine a miniature apartment building for cells, with tiny hallways for nutrients and test drugs to flow through. In scientific terms, the printed framework creates controlled pathways and architectures that let researchers position cells and fluids in ways that better mimic real tissue.
Making an artificial barrier with living cells
The printed platform is only part of the system. To create an artificial blood-brain barrier, the researchers grow the blood and tissue cells that form the barrier in the body directly on the 3D-printed structure.
That is what makes it an organ-on-a-chip rather than just a plastic device. The chip provides the structure, but the living cells supply the biological behavior that researchers want to measure when they test whether a drug can cross the barrier or damages it.
Why 3D printing changes the equation
Traditional lab models are often limited by the shapes and layouts that are easy to manufacture. 3D printing offers more freedom, allowing the team to build different channel patterns and physical architectures instead of relying on one standard geometry.
That flexibility could eventually support a more personalized kind of model. The researchers suggest that a synthetic blood-brain barrier might one day be customized to better match a patient’s own biology, which could make drug screening more informative for diseases that vary widely from person to person.
A multi-team collaboration
The project grew after early success led Virginia Tech researchers to broaden its scope. Schultz and Francisco C. Davalos saw room to expand the work, and they brought in Amrinder Nain, who already had relevant tools and had previously collaborated with Davalos.
Each group contributes a different piece of the system. Nain’s team makes the ultra-thin, nanoporous membrane mimics, Schultz’s team incorporates that membrane into the larger device, and Davalos’s team adds the cells and performs the biological testing.
The role of the membrane
The membrane is a crucial component because barriers in the body are not just walls; they are thin, selective interfaces. A nanoporous membrane is a film filled with extremely small holes that can help recreate how molecules and signals pass between different cellular compartments.
Think of it like a coffee filter made for biology, except much more precise and much thinner. In practice, the membrane helps organize where different cell types sit and how they interact, which is essential for reproducing the behavior of the blood-brain barrier.
Testing whether the model behaves like real tissue
After Schultz’s team builds the device around the membrane, the system is tested using a setup developed by Nadkarni’s team at Harvard. That step is meant to evaluate how the material behaves before the finished chips move on for biological experiments.
Only after that does Davalos’s group seed the device with cells and study the biology. This division of labor matters because organ-on-a-chip systems sit at the intersection of engineering and life science: the materials have to be safe for cells, the structure has to be manufacturable, and the biology has to act enough like the real organ to be useful.
Why This Matters
Drug testing often breaks down because common lab models are too simple. Cells grown in flat layers can reveal some basic effects, but they do not capture the architecture, fluid flow, and cell-to-cell interactions that shape how tissues behave inside the body.
Organ-on-a-chip devices aim to close that gap by giving researchers a small, controllable stand-in for living organs. If this Virginia Tech platform can reliably model the blood-brain barrier, it could help scientists screen brain-targeted drugs more realistically and extend the same approach to other organs where structure strongly influences function.
Nain said organ-on-a-chip technologies are on track to become standard laboratory protocols in the 21st century, and he described the team’s work as enabling what he called the thinnest BBB in the market. He added that future design iterations are expected to better match the dimensions and architectures found in the human body, with the aim of producing more physiological outputs in the lab.
That future is still being built, but the direction is clear. By combining precise manufacturing with living biology, the Virginia Tech-led collaboration is trying to turn organ models from rough approximations into practical testbeds that researchers can trust, first for the brain and potentially for many other parts of the body.